In the Original Investigation titled “Association of O6-Methylguanine-DNA Methyltransferase Protein Expression With Postoperative Prognosis and Adjuvant Chemotherapeutic Benefits Among Patients With Stage II or III Gastric Cancer,”1 the authors had failed to provide citations to and description of the previously published and related 9 studies; a more complete explanation of the role of Shanghai Outdo Biotech Co, Ltd, in creating the tissue microarrays and evaluating the immunohistochemistry scores; and a better explanation of the rationale for use of R software, version 3.3.2, in the Abstract, Introduction, Methods, and eMethods 1 and eMethods 2 in the Supplement. These omissions did not affect the conclusions of the article. A Letter of Explanation2 has been published that details the source of these errors. This article has been corrected online.
1.Cao
Y, Liu
H, Li
H,
et al. Association of O
6-methylguanine-DNA methyltransferase protein expression with postoperative prognosis and adjuvant chemotherapeutic benefits among patients with stage II or III gastric cancer.
JAMA Surg. 2017;152(11):e173120. doi:
10.1001/jamasurg.2017.3120PubMedGoogle ScholarCrossref